hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06278597 id: GLC02-22 briefTitle: Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device overallStatus: RECRUITING date: 2023-09-05 date: 2024-01-20 date: 2025-01-24 date: 2024-02-26 date: 2024-02-26 name: Fondazione G.B. Bietti, IRCCS class: OTHER briefSummary: The aim of the study is to evaluate an objective, non-invasive optical device able to quantify, without eye contact, the width of the irido-corneal angle and to better identify cases of narrow angle or angle closure that may be prevented with relatively simple treatments. conditions: Glaucoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 65 type: ESTIMATED name: NACA Estimator measure: Agreement between the automatic Narrow Anterior Chamber Angle Estimator grading of peripheral anterior chamber width with clinical grading as performed by Van Herick (VH) test at slit lamp measure: Agreement between the automatic Narrow Anterior Chamber Angle Estimator grading of peripheral anterior chamber width with clinical grading as performed by gonioscopy. measure: Reproducibility (intra-session) and repeatability (inter-session) of the peripheral anterior chamber width (PACW) evaluation by the Narrow Anterior Chamber Angle Estimator measure: Sensitivity and specificity of NACA Estimator grading of PACW in detecting primary angle closure suspects as classified by clinical gonioscopy. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Fondazione GB Bietti status: RECRUITING city: Roma zip: 00184 country: Italy name: Carmela Carnevale, MD role: CONTACT phone: +390677052834 email: carmela.carnevale@fondazionebietti.it name: Francesco Oddone, PhD role: CONTACT phone: +390677052834 email: francesco.oddone@fondazionebietti.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06278584 id: 2020001-00 briefTitle: iLux Treatment for Meibomian Gland Dysfunction acronym: MGD overallStatus: COMPLETED date: 2020-10-15 date: 2021-02-01 date: 2022-02-28 date: 2024-02-26 date: 2024-02-26 name: Clínica de Oftalmología de Cali S.A class: OTHER briefSummary: Summary:
Methods: Prospective, randomized, open-label, controlled clinical trial comparing one session of the ILux® MGD Treatment System versus five sessions of MMGE in both eyes of 130 patients aged ≥18 years with OSDI scores ≥13, total MGS of 15 in the lower lid of each eye and NI-TBUT \<10 s, who were randomized 1:1 to ILux® or MMGE. conditions: Meibomian Gland Dysfunction conditions: Eyes Dry Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 130 type: ACTUAL name: iLUX Treatment System measure: Effectiveness defined as changes from baseline to 1, 3, 6, 9 and 12 months in Non Invasive Tear break-up time (NI-TBUT) in seconds. measure: Effectiveness defined as changes from baseline to 1, 3, 6, 9 and 12 months in Meibomian gland scores (MGS). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clínica de Oftalmología de Cali S.A city: Cali state: Valle Del Cauca zip: 760036 country: Colombia lat: 3.43722 lon: -76.5225 hasResults: False
nctId: NCT06278571 id: R-2018-785-100 briefTitle: Effect of Education With Mobile App on Metabolic Control in Patients With Type 2 Diabetes overallStatus: RECRUITING date: 2023-01-30 date: 2025-04-30 date: 2025-12-03 date: 2024-02-26 date: 2024-02-26 name: Coordinación de Investigación en Salud, Mexico class: OTHER_GOV briefSummary: The objective of this study is to compare the effect of education through a mobile application with medical and nutritional reinforcement on the metabolic control of Mexican patients with type 2 diabetes attending primary care clinics in Mexico.
Patients with type 2 diabetes will be randomly assigned to the educational intervention through the educational site, (n=160 patients), two clinics will be assigned for the use of the mobile App and the educational site (n=160 patients), and two clinics will be part of the control group (n=160 patients). conditions: Female studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multicenter clinical trial primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Participants are unaware of other intervention arms whoMasked: PARTICIPANT count: 480 type: ESTIMATED name: Educational intervention with App and web site education name: Educational interventión with web site education name: Control group with nutritional therapy measure: Number of participants with glycosylated hemoglobin at control goals measure: Number of participants with iipid profile in control targets measure: Number of participants with body mass index profile in control target measure: Number of patients with changes to a healthy lifestyle measure: The proportion of patients with adequate knowledge of diabetes sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Instituto Mexicano Del Seguro Social status: RECRUITING city: Ciudad de mexico zip: 03100 country: Mexico name: LUBIA Velazquez, PhD role: CONTACT phone: 525523259424 email: lubia2002@yahoo.com.mx name: Gabriela Ortiz, Master role: CONTACT phone: 5543379062 email: lubia2002@yahoo.com.mx name: Abril V Muñoz, PhD role: SUB_INVESTIGATOR name: Jorge Escobedo, Phd role: SUB_INVESTIGATOR name: Ignacio Pineda, Master role: SUB_INVESTIGATOR lat: 19.42847 lon: -99.12766 hasResults: False
nctId: NCT06278558 id: 2023-02-01 briefTitle: Psychological Factors Influencing Cancer Post-traumatic Growth acronym: CEMA-P overallStatus: RECRUITING date: 2023-11-10 date: 2026-11-10 date: 2027-11-10 date: 2024-02-26 date: 2024-02-26 name: Centre Hospitalier de Valenciennes class: NETWORK name: Ligue contre le cancer, France name: Centre Oscar Lambret name: Centre de Cancérologie Les Dentellières name: Clinique Teissier briefSummary: The study focuses on post-traumatic growth (positive changes linked to appreciation of life, personal strengths, social relationships...) in the context of different types of cancer and with a longitudinal approach to the care pathway. The aim of the study is to better understand whether psychological variables (emotional competence, psychological flexibility, psychological distress) and patients' care satisfaction, assessed at the start of the cancer treatment pathway, can influence their post-traumatic growth at the end of the chemotherapy protocol and 6 months later. conditions: Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 289 type: ESTIMATED name: Interviews with a psychologist/psychiatrist measure: Post-traumatic growth measure: Post-traumatic growth measure: Post-traumatic growth measure: Satisfaction of supportive care needs measure: Satisfaction of supportive care needs measure: Satisfaction of supportive care needs measure: Emotional competence measure: Emotional competence measure: Emotional competence measure: Anxiety and depression symptoms measure: Anxiety and depression symptoms measure: Anxiety and depression symptoms measure: Psychological flexibility measure: Psychological flexibility measure: Psychological flexibility sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier de Valenciennes status: RECRUITING city: Valenciennes zip: 59300 country: France name: FODIL Hanane role: CONTACT phone: 0327140665 email: fodil-h@ch-valenciennes.fr name: Anne Sophie Baudry role: PRINCIPAL_INVESTIGATOR lat: 50.35 lon: 3.53333 hasResults: False
nctId: NCT06278545 id: MANFREDI PHRCK 2022 briefTitle: Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma acronym: FOLFORINOX SBA overallStatus: RECRUITING date: 2024-02-16 date: 2027-02 date: 2029-02 date: 2024-02-26 date: 2024-02-26 name: Centre Hospitalier Universitaire Dijon class: OTHER briefSummary: Randomized, non-comparative, open-label, multi-centre Phase II study to evaluate modified FOLFIRINOX and modified FOLFOX in the locally advenced or metastatic small bowel adenocarcinoma.
The primary objective is to assess the percentage of patients alive without prograssion at 8 months. conditions: Locally Advanced or Metastatic Small Bowel Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 130 type: ESTIMATED name: modified FOLFORINOX name: Modified FOLFOX measure: Assess the percentage of patients alive without progression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chu Dijon Bourgogne status: RECRUITING city: Dijon zip: 21000 country: France name: Sylvain MANFREDI role: CONTACT phone: +33 03 80 29 37 50 email: sylvain.manfredi@chu-dijon.fr lat: 47.31667 lon: 5.01667 hasResults: False
nctId: NCT06278532 id: NEGKOG briefTitle: Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS overallStatus: RECRUITING date: 2023-12-11 date: 2026-12-11 date: 2026-12-11 date: 2024-02-26 date: 2024-02-26 name: Lithuanian University of Health Sciences class: OTHER briefSummary: This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test. conditions: Schizophrenia conditions: Negative Symptoms in Schizophrenia conditions: Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis) conditions: Cognitive Deficit studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: Brief Negative Symptoms Scale name: The Calgary Depression Scale for Schizophrenia name: The Schizophrenia Cognition Rating Scale measure: Validated Lithuanian version of the Brief Negative Symptoms Scale. measure: Validated Lithuanian version of the Calgary Depression Scale for Schizophrenia. measure: Validated Lithuanian version of the Schizophrenia Cognition Rating Scale. measure: Correlation between negative symptoms and cognitive deficits of schizophrenia measure: Correlation between depressive symptoms and cognitive deficits of schizophrenia measure: Correlation between negative symptoms, cognitive deficits, depressive symptoms of schizophrenia and health-related quality of life sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lithuanian University of Health Sciences Hospital Kaunas Clinics status: RECRUITING city: Kaunas zip: LT-50161 country: Lithuania name: Jonas Montvidas role: CONTACT phone: +37066240919 email: jonas.montvidas@lsmu.lt name: Eimantas Zauka role: CONTACT phone: +37069220076 email: eimantas.zauka@kaunoklinikos.lt lat: 54.90272 lon: 23.90961 facility: Jonas Montvidas status: RECRUITING city: Kaunas zip: LT-53137 country: Lithuania name: Jonas Montvidas role: CONTACT phone: +37066240919 email: jonas.montvidas@lsmu.lt name: Algirdas Musneckis role: CONTACT phone: +37061378748 email: algirdas.musneckis@kaunoklinikos.lt lat: 54.90272 lon: 23.90961 hasResults: False
nctId: NCT06278519 id: CARAMBOLE briefTitle: CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE) acronym: CARAMBOLE overallStatus: RECRUITING date: 2024-03-01 date: 2026-09-01 date: 2026-09-01 date: 2024-02-26 date: 2024-03-12 name: Poitiers University Hospital class: OTHER name: Fédération Française de Cardiologie briefSummary: ST-Segment Elevation Myocardial infarction (STEMI) corresponding to acute occlusion of cornary artery is the most severe ischemic myocardial disease and a leading cause of mortality of heart failure worldwide. Although acute mortality from STEMI has decreased over the last decades, the prognosis remains pejorative and difficult to anticipate. The best management of STEMI patients depends of predictive factors of clinical prognosis and justifies an active research of these factors, in particular the mechanisms leading to deleterious left ventricular remodeling, myocardial inflammation, reperfusion injury including the no-reflow phenomenon which is a major determinant of heart failure. Cohorts of consecutive STEMI patients, with a comprehensive assessment of clinical, biological and imaging parameters are needed to offer the basis for new hypothese for research or interventions and to precisely evaluate the quality of care provided.
* questionnaire assessment regarding their quality of life, cognitive status,and socio-economic conditions at the acute phase and 1 year follow-up of their STEMI. conditions: Myocardial Infarction studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 150 type: ESTIMATED name: Blood, urinary and feces collection name: Cardiac MRI name: Quality of life and cognitive status questionnaire measure: Major Adverse cardiac Events (MACE) measure: Infarct size measure: Infarct size measure: No-reflow size measure: No-reflow size measure: Cardiac enzymes rate measure: Cardiac enzymes rate measure: Cardiac enzymes rate measure: Cardiac enzymes rate measure: Inflammatory markers rate measure: Inflammatory markers rate measure: Inflammatory markers rate measure: Inflammatory markers rate measure: Gut microbiota profiling measure: Gut microbiota profiling measure: Genitourinary microbiota profiling measure: Genitourinary microbiota profiling measure: EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version) measure: EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version) measure: Codex test measure: Codex test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: C.H.U. of Poitiers status: RECRUITING city: Poitiers zip: 86000 country: France name: Claire BOULETI, MD role: CONTACT phone: +33 5 49 44 43 25 email: claire.bouleti@chu-poitiers.fr lat: 46.58333 lon: 0.33333 hasResults: False
nctId: NCT06278506 id: 4612 briefTitle: Resection or Ablation of Small Kidney Tumors acronym: RESTART overallStatus: RECRUITING date: 2024-01-31 date: 2027-12 date: 2037-12 date: 2024-02-26 date: 2024-02-26 name: Karolinska University Hospital class: OTHER briefSummary: Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions. The purpose of the study is to compare complications, the frequency of residual tumors, impact on kidney function, differences in quality of life, and health economic factors in a randomised study. We will also compare the oncological outcomes, including survival and recurrence of kidney cancer. conditions: Kidney Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: RCT primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: Ablation name: Surgery measure: Number of participants with surgical complications according to Clavien-Dindo grade 2-5 measure: Radiological signs of a residual tumor at the 6-month follow-up measure: Number of postoperative hospitalization days (LOS) measure: Cancer-specific survival (CSS) measure: Overall survival (OS) measure: Change in eGFR one year after treatment sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Karolinska University Hospital status: RECRUITING city: Stockholm zip: 14186 country: Sweden name: Anders Kjellman, MD, PhD role: CONTACT phone: +46736995258 email: anders.kjellman@regionstockholm.se name: Per-Olof Lundgren, MD, PhD role: CONTACT lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06278493 id: AL2846-I-0002 briefTitle: A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer overallStatus: COMPLETED date: 2018-08-23 date: 2021-10-25 date: 2023-05-01 date: 2024-02-26 date: 2024-02-26 name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. class: INDUSTRY briefSummary: This is a clinical study to observe the tolerance and primary efficacy of AL2846 capsules combined with Gemzar injection in patients with pancreatic cancer, and to determine the recommended dosage and administration method for subsequent clinical studies. conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 34 type: ACTUAL name: AL2846 capsules name: Gemzar measure: Dose limiting toxicity (DLT) measure: Maximum tolerated dose (MTD) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Medical University Cancer Hospital city: Tianjin state: Tianjin zip: 300181 country: China lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06278480 id: LNC-MECA-003 briefTitle: Clinical Trial to Evaluate the Regeneration of Articular Cartilage Through Arthroscopy After MegaCarti® Application overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-23 date: 2024-02-29 date: 2024-02-29 date: 2024-02-26 date: 2024-02-26 name: L&C Bio class: INDUSTRY briefSummary: The MegaCarti® is the decellularized allogeneic cartilage and acts as a cover after bone marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by assisting in the location of stem cells derived from bone marrow. During the 48-week confirmatory clinical trial of MegaCarti®, patients who simultaneously underwent high tibial osteotomy(HTO) were treated with a group in which MegaCarti® was implanted after microfracture and a group in which microfracture alone was performed. Cartilage regeneration is evaluated in patients with arthroscopy data at the time of fixation removal surgery. conditions: Osteoarthritis, Knee studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: MegaCarti® name: microfracture measure: Comparison of the ICRS-Cartilage Repair Assessment grade-Overall repair assessment measure: Comparison of macroscopic status of regenerated cartilage measure: Comparison of IKDC score measure: Comparison of VAS score measure: Comparison of KOOS score measure: Comparison of WOMAC score measure: Comparison of Kellgren-Lawrence grade measure: Comparison of HKA angle, Posterior Tibial slope sex: ALL minimumAge: 19 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yonsei University Health System, Gangnam Severance Hospital city: Seoul zip: 06273 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06278467 id: KonyaBeyhekimTRH2023 briefTitle: Frequency of Cognitive Dysfunction in Patients With Chronic Low Back Pain overallStatus: COMPLETED date: 2022-03-01 date: 2023-12-15 date: 2024-02-12 date: 2024-02-26 date: 2024-02-26 name: Konya Beyhekim Training and Research Hospital class: OTHER_GOV briefSummary: This study evaluates cognitive dysfunction status and related factors in patients with chronic low back pain over the age of 60. conditions: Cognitive Dysfunction conditions: Low Back Pain studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 107 type: ACTUAL name: visual pain scale (VASpain/fatigue), Beck depression index (BDI), name: Pain catastrophizing scale, sleep quality with a single Likert type question in the Pittsburgh questionnaire name: Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36), name: Montreal Cognitive Assessment Scale (MOCA); Standard Mini mental test (SMMT) measure: Montreal Cognitive Assessment Scale (MOCA) measure: Standard Mini mental test (SMMT) measure: Short Form-36 ( SF-36) measure: Beck depression scale (BDI) measure: Roland Morris Disability Questionnaire measure: A single Likert type question in the Pittsburgh questionnaire (Sleep quality) measure: VAS pain and VAS fatigue measure: Pain catastrophizing scale sex: ALL minimumAge: 60 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Konya Beyhekim Training and Research Hospital city: Konya state: Selçuklu zip: 42060 country: Turkey lat: 37.87135 lon: 32.48464 facility: University of Health Sciences, Konya Beyhekim Training and Research Hospital, Department of Physical Medicine and Rehabilitation city: Konya zip: 42060 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06278454 id: NrtPac-1 id: CTR20240312 type: OTHER domain: Center for Drug Evaluation, NMPA briefTitle: Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-12 date: 2026-12 date: 2024-02-26 date: 2024-02-26 name: Chengdu New Radiomedicine Technology Co. LTD. class: INDUSTRY briefSummary: This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study. conditions: Unresectable Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 58 type: ESTIMATED name: NRT6008 Injection + Systematic chemotherapy measure: Maximum tolerated dose (MTD) or the recommended phase Ⅱ dose (RP2D) measure: Dose-limiting toxicity (DLT) measure: Adverse events (AE) and severe adverse events (SAE) measure: Objective response rate (ORR) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Resection rate (R0 and R1) measure: Concentration of tumor biomarkers measure: Numeric rating scale (NRS) of pain measure: Distribution of NRT6008 injection in human body and radioactivity of biological samples sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Henan Cancer Hospital city: Zhengzhou state: Henan country: China name: Suxia Luo role: CONTACT name: Suxia Luo role: PRINCIPAL_INVESTIGATOR lat: 34.75778 lon: 113.64861 facility: Second Affiliated Hospital of Soochow University city: Suzhou state: Jiangsu country: China name: Duanmin Hu role: CONTACT name: Duanmin Hu role: PRINCIPAL_INVESTIGATOR lat: 31.30408 lon: 120.59538 facility: Shanghai Changhai Hospital city: Shanghai state: Shanghai zip: +8602131162338 country: China lat: 31.22222 lon: 121.45806 facility: Chongqing University Cancer Hospital city: Chongqing country: China name: Weiqing Chen role: CONTACT name: Weiqing Chen role: PRINCIPAL_INVESTIGATOR lat: 29.56278 lon: 106.55278 facility: Tianjin Medical University General Hospital city: Tianjin country: China name: Bangmao Wang role: CONTACT name: Bangmao Wang role: PRINCIPAL_INVESTIGATOR lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06278441 id: Zila Özlem KIRBAŞ briefTitle: The Effect of White Noise and Kangaroo Care Practices on Stress Parameters in Newborns With Heel Lancing overallStatus: COMPLETED date: 2023-01-01 date: 2023-09-01 date: 2024-02-10 date: 2024-02-26 date: 2024-02-26 name: Karadeniz Technical University class: OTHER briefSummary: Aim: It is an examination of the effects of white noise and kangaroo care on some physiological parameters (pulse, saturation, crying duration) and stress markers (cortisol and glucose-regulated protein 78 (GRP78)) in heel lancing in newborns.